Complexa, Inc.

Pfizer Inc. 's commitment of an additional $600m to its corporate venture capital fund includes a plan to spend 25% on neuroscience investments – a curious move considering the company's decision at t

GlaxoSmithKline PLC 's chief financial officer Simon Dingemans has informed the board of his intention to retire and to step down from the board in May 2019. The board will now conduct a global se

While clearly lagging behind their US counterparts, European biotechnology companies and medtech firms across all stages of development can still attract significant venture capital if they are innova

Canaan Partners is an active investor in the biopharmaceutical space, even though it isn't focused specifically on life science or health care ventures, and now it has extra spending power after closi